Background {#Sec1}
==========

The worldwide outbreak of a new type of coronavirus disease (COVID-19) originated in Wuhan, China, in December 2019 and has rapidly spread in most countries in the world, despite governments' containment measures trying to minimize impact \[[@CR1], [@CR2]\]. However, despite global spread, the full clinical spectrum and epidemiological features of COVID-19, particularly in children, are still poorly described \[[@CR3]\]. The largest Chinese case series included 2143 children, but of these, only 34.1% (731) were laboratory-confirmed \[[@CR4]\]. Very few studies described COVID-19 among children in countries outside China. So far, only two contributes, in the form of research letters, on COVID-19 case series among children from European countries---specifically, Italy and Spain---have been released, and they included small samples and limited details on children characteristics \[[@CR5], [@CR6]\]. Although preliminary surveillance data on COVID-19 pediatric cases in the USA has been published, information on clinical presentation was available only in 9% of cases \[[@CR7]\]. In general, data from the national surveillance systems \[[@CR7]--[@CR9]\] often miss details on key clinical characteristics of children and their outcomes.

In this retrospective study, we aimed at describing the clinical presentation, diagnostic findings, type of respiratory support, and outcomes of a cohort of pediatric patients with confirmed COVID-19 virus infection in Italy, collected through two large collaborative research networks.

Methods {#Sec2}
=======

Population and settings {#Sec3}
-----------------------

Data were collected through two large collaborative research networks, including a group of pediatric Emergency Departments coordinated by Meyer Hospital in Florence, and a research network of pediatric hospitals/departments and family pediatricians, coordinated by the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy. Overall, the two networks comprised 61 centers: 53 (86.9%) hospitals and 8 (13.1%) outpatient centers. All children (aged 0--18 years) who presented to any of the recruiting centers between the 3rd and 26th of March 2020 and were diagnosed with COVID-19 were included in the study. Only three of the cases reported within the research network, all referred with very mild disease, could not be retrieved due to unavailability (sick leave) of the doctor who took in charge of them.

Cases were screened for COVID-19 virus infection based on national recommendations during the study period \[[@CR10]\]. COVID-19 virus infection was diagnosed using nasal or nasopharyngeal swab specimens collected by trained personnel in line with national recommendations and tested for COVID-19 virus nucleic acid in regional referral laboratories using WHO-recommended real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays.

Data collection {#Sec4}
---------------

Data were collected with a predefined, standardized, field-tested form. Clinical, laboratory, and imaging data were obtained from official medical records and entered in the form by staff at each hospital. Information for health workers on how to complete the form was embedded in the form itself. Data collection forms were checked in real time for internal consistency or missing data by trained personnel. Additional cross-check and data cleaning were done before data analysis, by an expert statistician (IM). Disease severity was classified adapting a previous published classification \[[@CR4]\], based on predefined criteria, as reported in Table [1](#Tab1){ref-type="table"}**.**Table 1Disease severity**Asymptomatic**: all the following must be present1. No signs or symptoms2. AND negative chest X-ray3. AND absence of criteria for other cases**Mild**: any of the following (AND absence of criteria for more severe cases)1. Symptoms of upper respiratory tract infection2. AND absence of pneumonia at chest X-ray**Moderate**: all the following (AND absence of criteria for more severe cases)1. Cough AND (sick appearing OR pneumonia at chest X-ray)**Severe**: any of the following (AND absence of criteria as for critical case)2. Oxygen saturation \< 92%3. OR difficult breathing or other signs of severe respiratory distress (apnea, gasping, head nodding)4. OR need for any respiratory support**Critical**: Any of the following1. Patient in ICU2. OR intubated3. OR multiorgan failure4. OR shock, encephalopathy, myocardial injury or heart failure, coagulation dysfunction, acute kidney injury.Adapted from Dong Y et al. \[[@CR4]\]

Data analysis {#Sec5}
-------------

Categorical variables were reported as absolute numbers and percentages and compared using the *χ*^2^, Fisher exact test, or Mantel-Haenszel correction as appropriate, and by calculating odds ratios (OR) with confidence intervals of 95% (95% CI). The significance level was set at 0.05 (two-tailed test). Continuous variables were expressed as means and standard deviations or as median and inter-quartile ranges (IQR), if not normally distributed. An exploratory subgroup analysis was performed on disease severity by age group. Data were analyzed with STATA 15.

Results {#Sec6}
=======

Overall, 130 children and adolescents with confirmed COVID-19 virus infection were included in the study from 28 centers within the participating networks covering 10 regions in Italy (Fig. [1](#Fig1){ref-type="fig"}). One hundred twelve (86.2%) cases were recruited at hospital level, and 18 (13.8%) at outpatient level.Fig. 1Distributions of enrolled COVID-19 cases across regions in Italy

Notably, among patients younger than 2 years, 35/41 (85.3%) were less than 6 months of age (Table [2](#Tab2){ref-type="table"}). Distribution by sex showed a slight male predominance (OR 1.63, 95% CI 1.00 to 2.68, *p* = 0.47). Overall, 70 (53.8%) of children had contact with a COVID-19 case, with most of these (67/70 (95.7%) reporting a relative with COVID-19. Thirty-four (26.2%) patients had comorbidities, with the most frequent being respiratory, cardiac, or neuromuscular chronic diseases (12% of all children).Table 2Sociodemographic characteristics and disease severity at presentation*N* = 130\
*N* (%)*p* valuesAge range0--17NAMedian age (IQR)6 (0--11)NAAge groups  \< 2 years41 (31.5%)*p* \> 0.05  2--9 years35 (26.9%)  10--17 years45 (34.6%)  Missing9 (6.9%)Sex  Male73 (56.2%)*p* = 0.47  Female57 (43.8%)Contact with COVID-19 positive70 (53.8%)NARelatives COVID-19 positive67 (51.5%)Comorbidities  Yes34 (26.2%)*p* \< 0.001  No92 (70.8%)  Missing4 (3.1%)Type of comorbiditiesNA  Respiratory, cardiac or neuromuscular chronic diseases16/130 (12.0%)  Pre-term3/130 (2.3%)  Immunodepression2/130 (1.4%)  Cerebral palsy1/130 (0.7%)  Others^1^12/34(10.0%)Disease severity  Asymptomatic17 (13.1%)  Mild81 (62.3%)  Moderate11 (8.5%)*p* \< 0.001  Severe11 (8.5%)  Critical9 (6.9%)  Missing1 (0.8%)Symptoms and signsNA  Fever67/130 (51.5%)  Dry cough38/130 (29.2%)  Productive cough16/130 (12.3%)  Rhinorrhea25/130 (19.2%)  Respiratory distress17/130 (13.0%)  Vomiting15/130 (11.5%)  Diarrhea10/130 (7.6%)  Sore throat9/130 (6.9%)  Thoracic pain4/130 (3.0%)  Hypo-reactive or hyperactive4/130 (3.0%)  Febrile convulsions2/130 (1.5%)  Otitis1/130 (0.7%)  Pains at lower limbs1/130 (0.7%)Oxygen saturation level at presentationNA  91--921/130 (0.8%)  ≤ 901/130 (0.8%)Laboratory test^1^71/130 (54.6%)NA  White blood cell count \< 5.5 (× 10^9^/L)7/19 (36.8%)  Lymphocyte count \< 1.2 (× 10^9^/L)3/19 (15.7%)  Aspartate aminotransferase \> 50 (U/L; 10--50)11/60 (18.3%)  Alanine aminotransferase \> 45 (U/L; 7--45)8/68 (11.8%)  Erythrocyte sedimentation rate \> 20 mm/h1/1 (100%)Chest X-ray ^1^41/130 (31.5%)NA  Ground-glass opacities17/41 (41.5%)  Negative15/41 (36.6%)  Focal consolidation4/41 (9.8%)  Missing description5/41 (12.1%)Decision after first visitNA  Discharged at home55/130 (42.3%)  Hospitalized75/130 (57.7%)Respiratory supportNA  Oxygen8/130 (6.1%)  High flow oxygen3/130 (2.3%)  Non-invasive ventilation2/130 (1.5%)  Intubation2/130 (1.5%)Cases in ICU9/130 (6.9.0%)OutcomeNA  Cured130/ (100%)  Dead0 (0%)*ICU* intensive care unit^1^Other comorbidities: among these 12 cases, only the following were specified: anemia \[[@CR2]\], thrombocytopenia, glucose-6-phosphate dehydrogenase deficiency (G6PDD) \[[@CR1]\], nephritis \[[@CR1]\], propionic acidemia \[[@CR1]\], autism \[[@CR1]\]

Most children were either asymptomatic (13.1%) or presented with mild disease (62.3%), while 11 (8.5%) had moderate disease, 11 (8.5%) had a severe disease, and 9 (6.9%) had a critical presentation.

Fever was recorded in 67 children (51.5%). The most common other symptom was cough, ether dry (29.2%) or productive (12.3%). Rhinorrhea was observed in 25 (19.2%). Respiratory distress was observed in 17 (13.0%). Two (1.6%) children were hypoxemic at presentation. Vomiting was reported in 15 (11.5%) and diarrhea in 10 (7.6%). Among children with vomiting, one had hematic vomit. Other signs or symptoms included sore throat (6.9%), thoracic pains (3%), hypo-reactivity (e.g., somnolence) or hyper-reactivity (e.g., excessive crying) (3%), febrile convulsions (1.5%), and pain in lower limbs (1.5%).

Out of the total sample of 130 children, 71 (54.6%) underwent laboratory testing. Among these patients, leucopenia and lymphopenia were detected in 36.8% and 15.7%, respectively, while increases in aspartate aminotransferase and alanine aminotransferase were reported in 18.3% and 11.8%, respectively.

Among the 41 (31.5%) children with chest X-ray, 17 (41.5%) showed ground-glass opacity, 15 (36.6%) presented a negative X-ray, and 4 (9.8%) had a focal consolidation.

Fifty-five (42.3%) children were treated at home and 75 (57.7%) were hospitalized.

Fifteen children needed some respiratory support: 8 (6.1%) needed oxygen, 3 (2.3%) high-flow oxygen, 2 (1.5%) non-invasive ventilation (CPAP), and 2 (1.5%) intubation and mechanical ventilation. Overall, nine (12.0%) children were admitted to intensive care unit (ICU).

Further characteristics of the children in the ICU are reported in Supplement [1](#MOESM1){ref-type="media"}. Out the nine cases in the ICU, six had an age below 6 months, and three were adolescents; seven were males. All children in the ICU were given some respiratory support, except for three cases, which were infants below 2 months of age (18, 31, and 41 days of life) with fever, and had either diarrhea, respiratory distress, or congenital conditions (anemia, congenital kidney malformation) plus a consolidation at chest X-ray. One adolescent with cerebral palsy, epilepsy tracheotomy, and enteral nutrition required mechanical ventilation. All children recovered, and none died.

Subgroup analysis (Table [3](#Tab3){ref-type="table"}) revealed that children below 6 months of age had a significantly increased risk of "critical" disease severity when compared with older children (6/35 (17.1%) vs 3/86 (3.5%), two-tailed Fisher test *p* = 0.034, OR 5.6, 95% CI 1.3 to 29.1).Table 3Disease severity by ageAsymptomaticMildModerateSevereCriticalMissingTotalAge group  \< 6 months2 (11.8%)20 (24.7%)4 (36.4%)3 (30.0%)*6 (60.0%)*0 (0.0%)35 (26.9%)  6--24 months1 (5.9%)4 (4.9%)0 (0.0%)1 (10.0%)0 (0.0%)0 (0.0%)6 (4.6%)  2--9 years7 (41.2%)21 (25.9%)4 (36.4%)3 (27.3%)0 (0.0%)0 (0.0%)35 (26.9%)  10--19 years7 (41.2%)27 (33.3%)3 (27.3%)4 (36.4%)*3 (33.3%)1 (100%)*45 (34.6%)  Missing0 (0.0%)9 (11.1%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)9 (6.9%)Total17 (100%)81 (100%)11 (100%)11 (100%)9 (100%)1 (100%)130 (100)Children below 6 months of age had a significantly increased risk of "critical" disease severity when compared with older children (6/35 (17.1%) vs 3/86 (3.5%)

Discussion {#Sec7}
==========

This paper adds to previous knowledge on COVID-19 in children, describing the characteristics and outcomes of a sample of children diagnosed with the disease in Italy. Official national statistics in Italy, when the study recruitment ended, reported 704 cases of COVID-19 among patients below 20 years, accounting for 1% of total cases diagnosed country-wide \[[@CR9]\]. The national surveillance system \[[@CR9]\] recorded, at time of study end, only 49 cases of children with COVID-19 hospitalized, compared with the 75 hospitalized cases reported by our research networks and described in this study. Furthermore, national reports in Italy only provide a description of cases by age, and no further details on other children characteristics are available \[[@CR9]\]. Major gaps in national surveillance data have been highlighted also in other countries, including the USA, with missing data on the variable of interest ranging from 9 to 91% of cases \[[@CR7], [@CR8]\]. This study, therefore, has the merit to identify a not negligible pediatric sample of COVID-19 cases in Italy, and characterized children by sociodemographic variables, comorbidities, severity of disease, clinical presentations, laboratory test, X-ray, and need of ventilatory support.

Case distribution across regions reflects voluntary participation of centers in the networks involved but is quite in line with the national distribution of cases of COVID-19, with Lombardy and Emilia-Romagna regions presenting the highest incidence of cases \[[@CR9]\].

The hospitalization rate in the sample of this study was significantly higher than what is reported in the official \[[@CR9]\] Italian statistics (57.7% vs 11.0%, *p* \< 0.05). Also, 26.2% of children in the sample of this study had comorbidities, a rate which is likely to be higher than the expected within the general pediatric population. Based on these observations, we believe that our sample is biased toward a more fragile population with more severe presentation, consistently with a network mostly including hospitals. When making comparison across different studies on pediatric COVID-19 case series, it is important to acknowledge differences in the characteristics of the sample and enrollment site \[[@CR4], [@CR8], [@CR11]\]. Specifically, in the largest study from China, most cases were diagnosed outpatient, and only 34.1% of cases were laboratory-confirmed \[[@CR4]\]. Conversely, the only existing reports on children from Spain \[[@CR5]\] are similar to our study, in the sense that children were mostly enrolled at hospital level; not surprisingly, hospitalization rate (60%) was similar to the rate observed in our study (57.7%). Early reports from the USA are difficult to interpret given the very high number of missing information \[[@CR7]\]. When comparing across populations, it is critical to remember that, so far, the real number of COVID-19 virus--positive cases in each of the countries of the world is currently unknown, and most probably heavily underestimated \[[@CR12]\]. Testing strategies and availability of diagnostic tests are largely variable across the globe, with Italy being among one of the countries with more test being performed, per million people \[[@CR13]\]. Additionally, the validity of the diagnostic test currently used (PCR on nasal or pharyngeal swab) is subject of debate \[[@CR14]\]. Therefore, the real incidence of COVID-19 severe and critical cases among the overall population, as well as the real hospitalization rate and the rate of cases in the ICU, is currently impossible to establish.

Results of this study confirm that COVID-19 in children is mostly a mild disease, however may have a not negligible rate of severe presentation in selected population of pediatric patients. Infants aged less than 6 months, especially males, seem significantly more susceptible to severe forms of the disease, in line with the previous Chinese case series \[[@CR4]\]. Specific risk factors, including specific underlying diseases, for hospitalization and treatment in ICU in children are currently poorly described. Evidence need to be generated to further establish the incidence of severe presentation of COVID-19 in infants and in children with pre-existing diseases. Additionally, criteria for hospitalization and for admission in ICU, which may vary by setting, should be further documented.

When compared with existing literature, this case series identifies few novel presentations of COVID-19 in children, including thoracic pain, hypo-reactivity or hyper-reactivity, febrile convulsions, and pain in lower limbs. Other possible rare manifestations of the diseases in children, such as liver and heart injury \[[@CR15]\], or skin rash \[[@CR16]\], or isolated gastrointestinal symptoms \[[@CR17]\], have been reported anecdotally and warrant further investigation.
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